Friday, 11 August 2017

#ClinicSpeak & #PoliticalSpeak: ageing the other elephant in the room

Do you think payers, or even regulators, would dare to be ageist in relation to MS treatments? #ClinicSpeak #PoliticalSpeak

Age, in particular old age (> 50 years of age), is a poor prognostic factor for MS and for most other neurological disorders. The aged brain does not deal with insults very well. Why? Age chews up brain and cognitive reserve and hence the capacity for the brain to recover from attacks is limited. I am convinced that a large part of the treatment response in DMT trials is driven by recovery of function, which may explain why in almost all studies the older you are the less effective the DMT. This is particularly evident in progressive MS trials, for example in the rituximab, ocrelizumab and siponimod trials. The implications of this is that when one these drugs get to market will NICE, and other payers, dare look at the cost-effectiveness of these treatments in older pwMS and decide that it is simply not worth paying for DMTs if you are above a certain age. 


Guillemin et al. Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study. Neuroepidemiology. 2017 Aug 10;48(3-4):179-187.


BACKGROUND: Late-onset multiple sclerosis (LOMS) frequently features a primary progressive (PP) course, strongly predicting severe disability. In this population-based cohort, we estimated the prognostic role of age at multiple sclerosis (MS) onset, independent of PP course, on disability progression.

METHODS: The association of age at disease onset (adult, <50 years [AOMS], vs. late, ≥50 years [LOMS]) and time to Expanded Disability Status Scale (EDSS) score 4 and 6 was estimated by Cox regression modelling.

RESULTS: Among 3,597 patients, 245 had LOMS. Relapsing-remitting (RR) disease was less frequent with LOMS than AOMS (51.8 vs. 90.8%, p < 0.0001). PP course, LOMS and male gender predicted short time to EDSS 4 and 6. Worse outcome with LOMS (time to EDSS 4 and 6, HR 2.0 [95% CI 1.7-2.4] and 2.3 [1.9-2.9]) was independent of PP course or male gender. LOMS had greater impact on RR than PP disease (time to EDSS 4 and 6, HR 3.1 [2.3-4.0] and 4.0 [2.9-5.6]). Only LOMS predicted time from EDSS 4 to 6 (p < 0.0001).


CONCLUSIONS: Late onset MS was strongly associated with poor prognosis, independent of initial disease course, in predicting the disability progression along time.

CoI: multiple

3 comments:

  1. Then introduce a dignity from dying legislative policy.

    MS will, inevitably destroy once it is progressive. These new meds will not cure it, just perhaps marginally slow it.

    Death via the NHSought to be an option.

    ReplyDelete
    Replies
    1. Jeez, take a happy pill. Trump and Kim Wrong-Un will maybe sort us all out anyway.

      Delete
  2. Or is LOMS more like 'missed earlier' MS? Perhaps date of earliest retrospective probable MS symptoms should be recorded rather than diagnosis date.
    No, I know this isn't workable. But it does mean that nothing much can be reliably taken from these comparison studies.

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.